Zifivax Vaccine to Undergo Mass Production Phase


PT Biotis Pharmaceutical Indonesia (Biotis) and PT Jakarta Biopharmaceutical Industry (JBio) are producing Zifivax or Anhui vaccine developed by a Chinese company, Anhui Zhifei Longcom Biopharmaceutical. Biotis President Director FX Sudirman revealed that the vaccine would be mass-produced at the factory located in Gunung Sindur, Bogor Regency, West Java.

He said that the fill and finish capacity of the Biotis factory could actually reach 20 million doses of vaccine per month. But the company plans to only produce 10 million doses in November and December so that by the end of 2021, 20 million doses will be available. "Actually, our factory is capable of producing 20 million vaccines per month. However, in the near future, we plan to also produce the Merah Putih Vaccine," Sudirman explained on Tuesday.

Start your free trial.

If you would like to get a 30-day free unlimited access to all of our insights, please click “Start free trial” button below. If you already have an account, please login.

What do subscribers receive?

As a subscriber, you’ll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Enjoy a 30-day free trial, on us. Feel free to contact us with any additional questions you have.